Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvogen And Pfenex Broaden Teriparatide Collaboration

Executive Summary

Alvogen and Pfenex have agreed to expand their existing US collaboration on Pfenex’ PF708 teriparatide candidate to also encompass the EU, certain MENA countries and other international markets.

You may also be interested in...



Ligand Snaps Up Pfenex For Half A Billion

Ligand Pharmaceuticals has struck a deal to acquire Pfenex in a transaction valued at up to $516m.

Kamada Licenses Alvotech Biosimilars In Israel

Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.

Alvogen Strikes Deals For Pfenex’ Teriparatide

Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.

Related Content

Topics

UsernamePublicRestriction

Register

GB140124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel